Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of TAK-788 (AP32788) in Non-Small Cell Lung Cancer
2016-001271-68Phase 2Unknown
- Sponsor
- Takeda
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mobocertinib in non-small cell lung cancer (NSCLC), sponsored by Takeda. Primary endpoints: Confirmed objective response rate (IRC, RECIST v1.1), Safety and tolerability and 1 more. Status: unknown.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-001271-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001271-68.